From Expanded Access to FDA Approval: What the Revolution Medicines Story Signals for Biopharma
Expanded Access is increasingly becoming an important part of the drug development and patient access conversation. A recent example from Revolution Medicines illustrates just how quickly an Expanded Access Program can move—and why pharmaceutical and biotechnology companies need the infrastructure to respond when patients and physicians are waiting.
Earlier this year, the FDA authorized an Expanded Access treatment protocol for Revolution Medicines' investigational therapy daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.
The speed of the FDA's response was notable.
The agency received Revolution Medicines' request on April 28, 2026. Just two days later, on April 30, the FDA issued a "safe to proceed" letter allowing the company to initiate the Expanded Access Program.
FDA Commissioner Marty Makary described the action as reflecting the agency's commitment to facilitating early access to therapies for patients with serious and life-threatening diseases.
But FDA authorization was only the beginning.
From Regulatory Authorization to Patient Access
Once an Expanded Access Program receives regulatory clearance, the challenge shifts from regulatory authorization to execution.
Revolution Medicines subsequently reported that it opened its FDA-cleared Expanded Access Program in May and began distributing daraxonrasib to participating treating physicians on behalf of patients within three weeks.
That timeline is significant.
Behind every Expanded Access request is a series of operational activities: physician intake, eligibility assessment, internal review, regulatory documentation, treatment coordination, drug supply, communication and ongoing patient management.
For organizations relying on disconnected spreadsheets, email threads and manual processes, coordinating those activities quickly can become increasingly difficult—particularly as demand grows.
The Revolution Medicines example demonstrates why the operational infrastructure surrounding Expanded Access matters.
Expanded Access as Part of the Therapy Lifecycle
The daraxonrasib story took another important step on August 26, 2026, when the FDA approved the therapy, marketed as Rasonque, for certain adults with metastatic pancreatic adenocarcinoma.
In announcing the approval, the FDA specifically referenced the Expanded Access protocol that had enabled patients to receive the investigational therapy before approval.
The progression is notable:
April 28: FDA receives the Expanded Access treatment protocol.
April 30: FDA allows the program to proceed.
May: Revolution Medicines launches the Expanded Access Program and begins distributing therapy within weeks.
August 26: FDA approves daraxonrasib for certain patients with metastatic pancreatic adenocarcinoma.
The circumstances surrounding every therapy are different, and Expanded Access is not a substitute for clinical trials or the FDA approval process. But this sequence provides a powerful example of the role Expanded Access can play during a critical period in a therapy's lifecycle.
When Regulatory Speed Meets Operational Readiness
The FDA's two-day action also highlights an important consideration for biopharma organizations.
If the regulatory pathway can move quickly, can the operational infrastructure supporting the program move just as quickly?
Once an organization decides to make an investigational therapy available through Expanded Access, teams may need to coordinate across Medical Affairs, Regulatory Affairs, Clinical Operations, supply, safety, legal and other functions.
They need processes for:
Receiving and evaluating physician requests consistently
Applying eligibility criteria
Managing approvals and required documentation
Coordinating treatment and drug supply
Tracking patients and treatment status
Communicating securely with requesting physicians
Managing country- and program-specific requirements
Maintaining complete, audit-ready records
Providing visibility across internal stakeholders
For a small number of requests, organizations may attempt to manage these processes manually.
As programs expand, however, those approaches can become difficult to scale.
Expanded Access Is Becoming an Infrastructure Question
The Revolution Medicines example highlights a broader shift in how biopharma companies may need to think about Expanded Access.
Expanded Access should not begin with the first patient request.
Organizations developing promising therapies can prepare earlier by establishing governance, defining decision-making processes, determining ownership and implementing systems capable of supporting a program if demand emerges.
That means asking questions such as:
Who owns the process?
How will requests be submitted and evaluated?
How will decisions and communications be documented?
How will supply be coordinated?
How will teams maintain visibility across patients and programs?
What happens when a handful of requests becomes dozens—or hundreds?
Answering those questions requires more than an Expanded Access policy. It requires operational infrastructure.
Technology's Role in Scaling Expanded Access
Purpose-built technology can help organizations move away from fragmented spreadsheets, inboxes and manual workflows toward a centralized approach to Expanded Access.
A dedicated platform can help organizations standardize intake, automate workflows, maintain appropriate governance, securely collaborate with healthcare professionals and create an audit-ready record across the lifecycle of each request.
At MedaSystems, we believe technology should do more than digitize existing processes. It should give Expanded Access and Medical Affairs teams the infrastructure they need to operate programs with greater consistency, visibility and control.
That becomes especially important when speed matters.
Preparing Before the Request Arrives
The Revolution Medicines story demonstrates what can happen when regulatory action and operational execution come together.
The FDA allowed the Expanded Access Program to proceed within two days. Revolution Medicines moved rapidly to make the therapy available to participating treating physicians. And several months later, the FDA approved daraxonrasib for certain patients with metastatic pancreatic cancer.
For other pharmaceutical and biotechnology companies, the lesson isn't that every Expanded Access Program will—or should—follow the same path.
It is that organizations should be prepared before the need arises.
Because when a physician is seeking an investigational therapy for a patient with a serious or life-threatening condition, the ability to move efficiently depends on more than regulatory authorization.
It depends on having the people, processes and technology ready to act.
